Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, Davis
About this trial
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Eligibility criteria
Qualifiers
Cohort A: prostate cancer
Cohort B: urothelial carcinoma
Cohort C: renal cell carcinoma
Provision of signed and dated informed consent form.
Disqualifiers
Medical comorbidities precluding locally ablative therapies.
History of treatment related toxicities that limit or prohibit application of locally ablative therapies.
Progressing intracranial lesions.
Trial design
Treatments tested in this trial
- Ablative local therapy
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
University of California, Davis
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov